Piper Sandler raised the firm’s price target on Guardant Health to $90 from $60 and keeps an Overweight rating on the shares. The firm surveyed 59 oncologists to gauge their views on profiling and market share. Overall, Piper thinks the survey is positive for companies such as Guardant Health (GH) and Tempus AI (TEM). The firm sees liquid biopsy, where it believes Guardant has a first-mover advantage, as growing even faster than CGP, and saw significant interest in it among different use cases.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- EXAS, GH, PLTR, SOFI: Cathie Wood Invests $5.5M in Exact Sciences, Trims Stakes in Guardant, Palantir, SoFi, and Other Big Names
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Guardant Health price target raised to $70 from $60 at Barclays
- Guardant Health announces FDA approved Guardant360 CDx
- Iron Mountain, Lennar, Sarepta, Paycom, Guardant: Trending by Analysts